Schond Greenway

Schond Greenway

Former Chief Financial OfficeratDefinium Therapeutics· In proxies 2022–2024

Pay in FY2022Definium Therapeutics stock -89.4% the same year

Schond Greenway was paid $2.1M in FY2022 (Dec). Definium Therapeutics stock fell 89.4% that year.

Pay$100 in the stock at the end of FY21 → $11
Pay is from the Summary Compensation Table of each Definium Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Definium TherapeuticsPublic company · 4 yr
    • Former Chief Financial Officer2022 – Present · 4 yrStock in role +55%

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?